Leveraging the Capabilities of Gamma Delta T Cells: Sebastian Wanless, MD, PhD

"As far as I'm aware, this is unique. The are no other companies or researchers that we know of who have developed a product where the CAR only has the co-stimulatory domain." —Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm

The FDA recently granted orphan drug designation to TC BioPharm for its unmodified allogeneic gamma delta T cell (GDT) product TCB-002 (OmnImmune) for the potential treatment of relapsed/refractory acute myeloid leukemia (AML).

The UK-based cell therapy company, which applies chimeric antigen receptor (CAR) T-cell technology to GDT cells in an effort to make the therapeutic more selective, is also moving toward clinical trials for treatments for a range of cancers, as well as infectious diseases.

Joining CGTL to discuss updates on its clinical programs is Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm.